Healthcare · Medical - Diagnostics & Research
Price
$191.14
Market Cap
$31.9B
Employees
89,000
Beta
1.22
Avg Volume
1,742,384
CEO
Ari Bousbib
Business Description
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Business History
Price Overview
Last updated: Jun 27, 2026 10:05am (just now)$191.14
+4.71 (+2.53%)
Day Range
$185.43 – $191.38
52-Week Range
$154.50 – $247.05
50-Day MA
$174.07
200-Day MA
$195.16
Volume
1,016,816.00
Analyst Price Targets
Low
$185.00
Consensus
$219.44
High
$250.00
(55 analysts)
Share Structure
Outstanding
166,900,000.00
Float
158,549,993.00
Free Float
95.0%
High free float
— 95.0% of shares trade freely, ~5% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
23.24
Stock Price: $191.14
EPS (Diluted): 7.91
EPS (Diluted): 7.91
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
5.96
Stock Price: $191.14
Total Equity: $6.50B
Shares: 173,500,000
Total Equity: $6.50B
Shares: 173,500,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
13.08
Market Cap: $31.90B
Total Debt: $15.95B
Cash: $1.98B
EBITDA: $3.46B
Total Debt: $15.95B
Cash: $1.98B
EBITDA: $3.46B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$52.9B
Market Cap: $31.90B
Total Debt: $15.95B
Cash: $1.98B
Total Debt: $15.95B
Cash: $1.98B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
26.3%
Gross Profit: $4.29B
Revenue: $16.31B
Revenue: $16.31B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
14.0%
Operating Income: $2.29B
Revenue: $16.31B
Revenue: $16.31B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
8.3%
Net Income: $1.36B
Revenue: $16.31B
Revenue: $16.31B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
22.5%
Net Income: $1.36B
Total Equity: $6.50B
Total Equity: $6.50B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
8.4%
Operating Income: $2.29B
Tax Rate: 15.6%
Equity: $6.50B
Total Debt: $15.95B
Cash: $1.98B
Tax Rate: 15.6%
Equity: $6.50B
Total Debt: $15.95B
Cash: $1.98B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.75
Current Assets: $6.25B
Current Liabilities: $8.34B
Current Liabilities: $8.34B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
2.45
Short-Term Debt: $1.84B
Long-Term Debt: $14.11B
Total Debt: $15.95B
Total Equity: $6.50B
Long-Term Debt: $14.11B
Total Debt: $15.95B
Total Equity: $6.50B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$94.01
Revenue: $16.31B
Shares: 173,500,000
Shares: 173,500,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$37.48
Total Equity: $6.50B
Shares: 173,500,000
Shares: 173,500,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$11.82
Operating CF: $2.65B
CapEx: -$603.00M
Shares: 173,500,000
CapEx: -$603.00M
Shares: 173,500,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $191.14
Stock Price: $191.14
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $1.36B
Net Income: $1.36B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IQV against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B |
| Cost of Revenue | $9.2B | $9.4B | $9.7B | $10.0B | $12.0B |
| Gross Profit | $4.6B | $5.0B | $5.2B | $5.4B | $4.3B |
| Operating Expenses | $3.2B | $3.2B | $3.3B | $3.2B | $2.0B |
| Operating Income | $1.4B | $1.8B | $2.0B | $2.2B | $2.3B |
| Net Income | $966.0M | $1.1B | $1.4B | $1.4B | $1.4B |
| EBITDA | $2.8B | $2.9B | $3.3B | $3.5B | $3.5B |
| EPS | $5.05 | $5.82 | $7.39 | $7.57 | $7.91 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.4B | $1.2B | $1.4B | $1.7B | $2.0B |
| Total Current Assets | $4.8B | $5.0B | $5.6B | $5.8B | $6.2B |
| Total Assets | $24.7B | $25.3B | $26.7B | $26.9B | $29.9B |
| Current Liabilities | $5.2B | $5.6B | $6.5B | $7.0B | $8.3B |
| Long-Term Debt | $12.0B | $12.6B | $13.0B | $12.8B | $14.1B |
| Total Liabilities | $18.6B | $19.6B | $20.6B | $20.8B | $23.3B |
| Total Equity | $6.0B | $5.8B | $6.1B | $6.1B | $6.5B |
| Retained Earnings | $2.2B | $3.3B | $4.7B | $6.1B | $7.4B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.9B | $2.3B | $2.1B | $2.7B | $2.7B |
| Capital Expenditure | -$640.0M | -$674.0M | -$649.0M | -$602.0M | -$603.0M |
| Free Cash Flow | $2.3B | $1.6B | $1.5B | $2.1B | $2.1B |
| Acquisitions (net) | -$1.5B | -$1.3B | -$876.0M | -$710.0M | -$1.8B |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$406.0M | -$1.2B | -$992.0M | -$1.4B | -$1.2B |
| Net Change in Cash | -$448.0M | -$150.0M | $160.0M | $326.0M | $278.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:05am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$18.3B $18.0B – $18.8B
|
$19.2B $19.2B – $19.3B
|
$20.4B $20.2B – $20.8B
|
$21.4B $21.2B – $21.8B
|
| EBITDA |
$3.9B $3.8B – $4.0B
|
$4.1B $4.0B – $4.1B
|
$4.3B $4.3B – $4.4B
|
$4.5B $4.5B – $4.6B
|
| Net Income |
$2.5B $2.4B – $2.6B
|
$2.8B $2.4B – $3.2B
|
$3.1B $3.1B – $3.2B
|
$3.5B $3.5B – $3.6B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +3.9% | +4.0% | +2.8% | +5.9% |
| Gross Profit Growth | +8.3% | +4.2% | +2.6% | -20.3% |
| Operating Income Growth | +29.1% | +9.9% | +11.4% | +3.9% |
| Net Income Growth | +12.9% | +24.5% | +1.1% | -0.9% |
| EBITDA Growth | +5.1% | +11.9% | +6.1% | +0.3% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-07 | Wims Morris Leslie | A-Award | 171.00 | $0.00 | $0 |
| 2026-05-07 | GOGGINS COLLEEN A | A-Award | 214.00 | $0.00 | $0 |
| 2026-05-07 | Fasano Jim | A-Award | 228.00 | $0.00 | $0 |
| 2026-05-07 | DANHAKL JOHN G | A-Award | 185.00 | $0.00 | $0 |
| 2026-04-23 | Stamps Sheila A | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | Wims Morris Leslie | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | Kaelin William G Jr | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | LEONARD JOHN M | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | GOGGINS COLLEEN A | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | Fasano Jim | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | DANHAKL JOHN G | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-04-23 | Burt Carol | A-Award | 1,571.00 | $0.00 | $0 |
| 2026-02-13 | Haas Bernd | F-InKind | 20.00 | $166.94 | $3,339 |
| 2026-02-13 | Fedock Michael J. | F-InKind | 123.00 | $166.94 | $20,534 |
| 2026-02-09 | STAUB W RICHARD | A-Award | 26,088.00 | $192.67 | $5.0M |
| 2026-02-09 | Sherbet Eric | A-Award | 12,112.00 | $192.67 | $2.3M |
| 2026-02-09 | Patel Bhavik | A-Award | 11,180.00 | $192.67 | $2.2M |
| 2026-02-09 | Haas Bernd | A-Award | 11,180.00 | $192.67 | $2.2M |
| 2026-02-09 | Grenfell Alistair | A-Award | 26,088.00 | $192.67 | $5.0M |
| 2026-02-09 | Fedock Michael J. | A-Award | 18,634.00 | $192.67 | $3.6M |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IQV — it's generated by the pipeline (
market-narrative step).
No community reviews yet for IQV.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30